Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Valentine M Ferré und 9 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Inserm UMR_1137, IAME, Paris, France. Hauptthemen laut MEDLINE: HIV Infections, Sexual and Gender Minorities, Sex Workers, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
No data about antiretroviral (ARV) treatment coverage and virological response are available among key populations (female sex workers [FSW] and Men having Sex with Men [MSM]) in Togo. This study aimed to both describe Human Immunodeficiency Virus (HIV) immunovirological status and evaluate the pertinence of an original algorithm combining pharmacology (PK) and viral load (VL) to identify subjects at risk of ARV drug resistance. A cross‐sectional multicentric study was conducted in 2017 in Togo. Our PK‐virological algorithm (PK‐VA) defines subjects at risk of resistance when exhibiting both detectable plasma drug concentrations and VL > 200 c/mL. Among the 123 FSW and 136 MSM included, 50% and 66% were receiving ARV, with 69% and 80% of them successfully‐treated, respectively. Genotypes showed drug‐resistance mutation in 58% and 63% of nonvirologically controlled (VL > 200 c/mL) ARV‐treated FSW and MSM, respectively. PK‐VA would have enabled to save 75% and 72% of genotypic tests, for FSW and MSM, respectively. We reported first data about HIV care cascade among key populations in Togo, highlighting they are tested for HIV but linkage to care remains a concern. Furthermore, 70%−80% of ARV‐treated participants experienced virological success. In limited resources settings, where genotyping tests are beyond reach, PK‐VA might be an easiest solution to sort out patients needing ARV adaptation due to resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, Inserm UMR_1137, IAME, Paris, France.
- Service de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.
- Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo.
- National Institute for Health and Medical Research (INSERM) UMR 1219, University of Bordeaux, Bordeaux, France.
- Service de Pharmacologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.
- Université Paris Cité and Université Sorbonne Paris Nord, INSERM, Paris, France.
ORCID-Profile: Valentine M Ferré
Zitieren
APA
Ferré, V. M., Bitty-Anderson, A. M., Peytavin, G., Lê, M. P., Dagnra, C. A., Coppée, R., Gbeasor-Komlanvi, F. A., Descamps, D., Charpentier, C., & Ekouevi, D. K. (2023). Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo. Journal of Medical Virology. https://doi.org/10.1002/jmv.28535
Vancouver
Ferré VM, Bitty-Anderson AM, Peytavin G, Lê MP, Dagnra CA, Coppée R, et al. Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo. Journal of Medical Virology. 2023. doi:10.1002/jmv.28535
BibTeX
@article{Ferr2023,
author = {Ferré, Valentine M and Bitty-Anderson, Alexandra M and Peytavin, Gilles and Lê, Minh P and Dagnra, Claver A and Coppée, Romain and Gbeasor-Komlanvi, Fifonsi A and Descamps, Diane and Charpentier, Charlotte and Ekouevi, Didier K},
title = {Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28535}
}
EUVIMED